A Related Analyst Comments
-
Goldman Sachs Maintains Buy on Agilent (A), Calls Q2 'Benign'
-
Agilent (A) Should Consider Split, Says ISI
-
Goldman Maintains Above Consensus View on Agilent's (A) Earnings Power
-
Barclays Lowers Estimates on Agilent (A); Execution...with a Turbo Lag
-
UBS Maintains a 'Buy' on Agilent (A) Despite Q3 Shortfall and a More Challenging Outlook
-
Jefferies Maintains a 'Buy' on Agilent (A), Citing Franchise Value; Chops Numbers on Tough Headwinds
-
Jefferies Maintains a 'Buy' on Agilent (A); Nail-Biter Heading Into Q3 Report
-
Jefferies Maintains a 'Conviction-List Buy' on Agilent (A); Valuation Remains Highly Compelling
-
Barclays Reiterates an 'Overweight' on Agilent (A) Given Multiple Long-Term Revenue Growth Drivers
-
UBS Maintains a 'Buy' on Agilent (A); Shareholder Friendly Dividend Initiation Justifies Higher Valuation
-
Barclays 2012 Top Picks: Becoming Somewhat More Optimistic - Signs of Progress, Growth and Soft Landings
-
Barclays Maintains an 'Overweight' on Agilent (A); Strong Guidance Lifts Overhang
-
Jefferies Cuts Price Targets on Agilent (A) Due to a Lower Cash Flow Forecast
-
Barclays on U.S. Life Science Tools: Q3 Preview: Is Sentiment Near a Bottom?
-
Needham & Company Maintains a 'Buy' on LTX-Credence (LTXC); Teradyne (TER) Purchases LitePoint for Big Premium; No Direct Impact on LTXC
-
Barclays Maintains an 'Overweight' on Agilent (A); Solid Execution & Favorable End-Market Mix
-
Jefferies Comments on Agilent (A) Following Strong Q3 Earnings and FY12 Outlook
-
Barclays on U.S. Life Science Tools: Q2 Preview; Favorites are A, ILMN, WAT
-
Barclays Reiterates an 'Overweight' on Agilent (A); LSG Conference Call: Key Takeaways
-
Barclays Maintains an 'Overweight' on Waters Corp. (WAT); H-class Within the Broader Acquity Strategy
-
Barclays Maintains an 'Overweight' on Agilent (A); LSG: The Next Leg of the Story
-
Credit Suisse Raises Price Target on Agilent (A) to $59, But Sees $66 on Upside Potential
-
Goldman Sachs Lifts Numbers On Agilent (A), But Maintains Neutral Rating
-
Jefferies Maintains a 'Buy' on Agilent (A); Ignore The Chart, Just Buy The Stock!
-
Barclays Maintains an 'Overweight' on Agilent (A); LSG - The Next Leg Of The Agilent Story
-
Jefferies Lifts Numbers on Agilent (A) Following Investor Meetings
-
Barclays on Life Science Tools: Q1 2011 Preview; Waters (WAT) And Agilent (A) Are Top Picks
-
Credit Suisse Raises Price Target, Estimates on Arrow (ARW); Difficult to Calculate Japan Impact
-
Barclays on U.S. Life Science Tools: PITTCON 2011 Review
-
Barclays Maintains an 'Overweight' on Agilent (A); A Turbo-Charged, Well-Oiled Machine
-
Barclays Reiterates an 'Overweight' on Agilent (A); Top 5 Issues for the March 3rd Analyst Day
-
Barclays Maintains an 'Overweight' on Agilent (A); Operational Execution Drives 2011 Outlook
-
Goldman Raises Estimates & Price Target on Agilent (A), Maintains Neutral Rating
-
Credit Suisse Maintains an 'Outperform' on Agilent (A); Bottom line - Electronics Test Still Rules Agilent's Business Model
-
Jefferies Raises Price Target & Estimates on Agilent (A), Maintains Buy Rating
-
Barclays Maintains an 'Overweight' on Agilent (A); Bullish After Europe Trip With Management
-
Needham & Company Reiterates a 'Buy' on LeCroy (LCRY); Recent Equity Offering Effectively Removes Debt Overhang
-
Barclays Maintains an 'Overweight' on Agilent (A); 2011: The Year Varian Comes Into Its Own
-
Jefferies Raises Estimates and Price Target on Agilent (A), Maintains Buy Rating
-
Barclays Maintains an 'Overweight/Top Pick' Rating on Agilent Technologies (A); Underappreciated EMG Spells Opportunity
-
UBS Maintains a 'Neutral' on Bruker Corp (BRKR); Sees Acquisition of Varian Assets Accretive to 2010-11
-
FBR Research Maintains a 'Market Perform' on Agilent Technologies (A); Raises PT & Estimates Citing Emerging Market Strength
-
Merriman Curhan Ford Reiterates a 'Buy' on NetScout Systems (NTCT); Quantifying the Mobile Opportunity
-
Brigantine Advisors Reiterates a 'Buy' on Ixia (XXIA); Expects Evidence of Improving Top Line Growth
-
Leerink Swann Comments On BRKR and TMO Following VARI/A Deal
-
Jim Cramer Makes Positive Comments on Verigy Ltd. (VRGY) and Novelis Inc. (NVL)
-
Agilent (A) Option implied volatility Elevated into EPS on 8/14
Back to A Stock Lookup
